Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) announced a scientific team, led by principal scientist Dr. Justin Chun at the University of Calgary, report in the peer-reviewed journal Inflammation Research that interleukin-32 (IL-32), a novel lipid droplet-associated cytokine, may contribute to tubular injury and inflammation in diabetic kidney disease (DKD).
The findings from human kidney tissue show that in DKD, kidney cells accumulate lipid (fat) droplets coated with the cytokine IL-32. This accumulation is believed to promote kidney injury and inflammation, identifying IL-32 as a potential link between metabolic dysregulation and inflammatory pathways that drive DKJD and other chronic diseases.
In the publication titled “Spatial transcriptomics identifies IL-32 as a lipid droplet-associated cytokine linked to tubular injury in human diabetic kidney disease”, the authors wrote, “IL-32 is a LD-associated cytokine upregulated during tubular injury that represents a potential link between lipid dysregulation, inflammation, and progression in human DKD.”
